Marker Therapeutics (Nasdaq:MRKR) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MRKR Overzicht aandelen

MRKR fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 81.05% per jaar groeien

De winst is de afgelopen 5 jaar met 41% per jaar gegroeid

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 23.5% per jaar dalen.

Heeft minder dan 1 jaar cash runway

Heeft geen zinvolle omzet ( $4M )

Heeft geen betekenisvolle marktkapitalisatie ( $25M )

+ 2 meer risico's

Marker Therapeutics, Inc. Concurrenten

Synlogic

NasdaqCM:SYBX

US$17.8m

MEI Pharma

NasdaqCM:MEIP

US$18.3m

Lumos Pharma

NasdaqGM:LUMO

US$29.8m

Aadi Bioscience

NasdaqCM:AADI

US$48.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Marker Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$2.65
52 Week Hoogtepunt	US$6.16
52 Week Laag	US$2.40
Bèta	1.54
11 maand verandering	-12.72%
3 maanden verandering	-46.61%
1 Jaar Verandering	-30.17%
33 jaar verandering	-83.92%
5 jaar verandering	-93.94%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29

Marker Therapeutics EPS misses by $0.02

Nov 09

Rendement voor aandeelhouders

	MRKR	US Biotechs	US Markt
7D	-3.5%	-1.6%	-0.7%
1Y	-30.2%	17.6%	32.5%

Rendement versus industrie: MRKR presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 22.1 % opleverde.

Rendement versus markt: MRKR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is MRKR's price volatile compared to industry and market?
MRKR volatility
MRKR Average Weekly Movement	12.2%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiele aandelenkoers: De aandelenkoers van MRKR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van MRKR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	8	Juan Vera	markertherapeutics.com

Marker Therapeutics, Inc. is een immuno-oncologisch bedrijf in een klinische fase dat zich bezighoudt met de ontwikkeling en commercialisering van nieuwe immuuntherapieën op basis van T-cellen voor de behandeling van hematologische maligniteiten en solide tumoren. Zijn multitumorgeassocieerde antigeenspecifieke T-celtechnologie is gebaseerd op de productie van niet-gemanipuleerde tumorspecifieke T-cellen die meerdere tumorgeassocieerde antigenen herkennen. Het bedrijf ontwikkelt ook MT-401-OTS voor de behandeling van acute myeloïde leukemie en MT-601 voor de behandeling van lymfomen en alvleesklierkanker.

Marker Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Marker Therapeutics zich tot de beurswaarde?
MRKR fundamentele statistieken
Marktkapitalisatie	US$23.11m
Inkomsten(TTM)	-US$10.31m
Inkomsten(TTM)	US$3.73m

6.4x

P/S-verhouding

-2.3x

Koers/Winstverhouding

Is MRKR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MRKR resultatenrekening (TTM)
Inkomsten	US$3.73m
Kosten van inkomsten	US$9.57m
Brutowinst	-US$5.85m
Overige uitgaven	US$4.46m
Inkomsten	-US$10.31m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.16
Brutomarge	-156.82%
Nettowinstmarge	-276.53%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde MRKR op de lange termijn?

Bekijk historische prestaties en vergelijking

MRKR Overzicht aandelen

Beloningen

Risicoanalyse

Marker Therapeutics, Inc. Concurrenten

NasdaqCM:SYBX

US$17.8m

NasdaqCM:MEIP

US$18.3m

NasdaqGM:LUMO

US$29.8m

NasdaqCM:AADI

US$48.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Recent updates

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Marker Therapeutics Announces U.S. Food and Drug Administration Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Earnings beat expectations, revenue disappoints

Marker Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Trial of Mt-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

New 90-day high: US$3.19

Marker shares rise as it completes construction of its cGMP manufacturing facility

New 90-day high: US$1.79

Marker Therapeutics, Inc. Announces U.S. Food and Drug Administration Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.75

Earnings beat expectations

Marker Therapeutics EPS misses by $0.02

New 90-day low: US$1.43

New 90-day low: US$1.50

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from S&P Global BMI Index

New 90-day low - US$1.65